

LAHIVE  
&  
COCKFIELD  
LLP



CONSULTORS AT LAW  
28 STATE STREET  
BOSTON, MASSACHUSETTS 02109-1784  
TELEPHONE (617) 227-7400  
FAX (617) 742-4214  
lc@lahive.com

JOHN A. LAHIVE, JR. (1928-1997)  
THOMAS V. SMURZYNSKI  
RALPH A. LOREN  
GIULIO A. DeCONTI, JR.  
ANN LAMPORT HAMMITTE  
ELIZABETH A. HANLEY  
AMY BAKER MANDRAGOURAS  
ANTHONY A. LAURENTANO  
KEVIN J. CANNING  
JANE E. REMILLARD  
DeANN FORAN SMITH  
PETER C. LAURO  
JEANNE M. DIGIORGIO  
DEBRA J. MILASINCIC, Ph.D.  
DAVID J. RIKKERS  
DAVID R. BURNS  
JOHN S. CURRAN  
SEAN D. DETWEILER

CYNTHIA L. KAI, Ph.D.  
MEGAN E. WILLIAMS, Ph.D.  
RICH A. NAND  
MICHAEL PHILLIPPS  
LISA M. DIROCCO  
HATHAWAY P. RUSSELL \*\*\*

SENIOR COUNSEL  
JAMES E. COCKFIELD

OF COUNSEL  
JEREMIAH LYNCH  
WILLIAM A. SCOFIELD, JR.

PATENT AGENTS  
THEODORE R. WEST  
SHAYNE Y. HUFF, Ph.D.  
DANIEL B. KO

1623  
TECHNICAL SPECIALISTS  
MARIA LACCOTRIPE ZACHARAKIS, Ph.D. \*\*  
CYNTHIA M. SOROOS  
PETER W. TANI, Ph.D.  
EUIHOON LEE  
JENNIFER K. ROSENFIELD  
ALLAN TAMESHTIT, Ph.D.  
CATHERINE E. McPHERSON  
ERIC F. WAGNER, Ph.D.  
SHAHID HASAN, Ph.D.  
JACOB G. WEINTRAUB  
PETER A. DIMATTIA  
JONATHAN M. SPARKS, Ph.D.  
CRISTIN E. HOWLEY, Ph.D.  
VINCENT P. LOCCISANO  
MERIDETH C. ARNOLD

\* Admitted in NY only  
\*\* Passed the Patent Bar Examination  
\*\*\* Admitted in TX only

November 13, 2001

Commissioner for Patents  
Washington, D.C. 20231

Re: U.S. Patent Application Serial No.: 09/852,400  
Compositions, Kits, and Methods for Identification,  
Assessment, Prevention, and Therapy of Psoriasis  
Inventors: William L. Trepicchio et al.  
Filed: May 9, 2001  
Our Ref. No.: GFN-5405CP

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

1. Information Disclosure Statement;
2. PTO Form 1449;
3. Copies of references cited in PTO Form 1449; and
4. A Return Postcard.

No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on:

November 13, 2001

Date

Amy E. Mandragouras, Esq. Reg. No. 36,207

Respectfully submitted,  
LAHIVE & COCKFIELD, LLP

Amy E. Mandragouras, Esq.  
Reg. No. 36,207  
Attorney for Applicants



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

JAN 07 2002

RECEIVED

Application of: William L. Trepicchio et al.

Group Art Unit: 1623

Serial No.: 09/852,400

Examiner:

Filed: May 9, 2001

For: Compositions, Kits, and Methods for  
Identification, Assessment, Prevention, and Therapy  
of Psoriasis

Attorney Docket No.: GFN-5405CP

Commissioner for Patents  
Washington, D.C. 20231

Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

11/13/01

Date of Signature and of Mail Deposit

By:

Amy E. Mandragouras, Esq.  
Reg. No. 36,207  
Attorney for Applicants

INFORMATION DISCLOSURE STATEMENT

Dear Sir:


Applicants and their attorney are aware of the following publications and information, listed on the attached PTO Form 1449, and in accordance with 37 CFR §1.97 hereby submit these publications for the Examiner's consideration. A copy of each cited publication is enclosed.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicants understand that the Examiner will make an independent evaluation of the cited publications.

Under 37 CFR § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR §1.17(p) to our Deposit Order Account No. 12-0080.

Respectfully submitted,

LAHIVE & COCKFIELD, LLP




Amy E. Mandragouras, Esq.  
Reg. No. 36,207  
Attorney for Applicants

28 State Street  
Boston, MA 02109  
(617) 227-7400

Date: **November 13, 2001**

AEM/CLK/SXH/ipc  
Enclosures

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO <b>GFN-5405CP</b>	SERIAL NO. <b>09/852,400</b>
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT <b>William L. Trepicchio et al.</b>	FILING DATE <b>May 9, 2001</b>
	GROUP <b>1623</b>	



## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

## OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

A1	Balendran N, et al. Characterization of the major susceptibility region for psoriasis at chromosome 6p21.3. J Invest Dermatol. 1999 Sep;113(3):322-8
A2	Brown RM, et al. Transfection screening for primary defects in the pyruvate dehydrogenase E1alpha subunit gene. Hum Mol Genet. 1997 Aug;6(8):1361-7
A3	Capon F, et al. Evidence for interaction between psoriasis-susceptibility loci on chromosomes 6p21 and 1q21. Am J Hum Genet. 1999 Dec;65(6):1798-800
A4	Coven TR, et al. Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B. Arch Dermatol. 1997 Dec;133(12):1514-22
A5	Czubayko F, et al. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat Med. 1997 Oct;3(10):1137-40
A6	Eisen MB, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8
A7	Fredriksson T, et al. Severe psoriasis--oral therapy with a new retinoid. Dermatologica. 1978;157(4):238-44
A8	Golub TR, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999 Oct 15;286(5439):531-7
A9	Gottlieb SL, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995 May;1(5):442-7
A10	Gottlieb AB, et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol. 1992 Mar;98(3):302-9
Examiner _____ Date Considered _____	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

RECEIVED

JAN 07 2002  
ECHO CENTER 1600/290

SERIAL NO.

REV 7-80

**GFN-5405CP**

69/852400

~~LIST OF PUBLICATIONS CITED BY APPLICANT~~

Use several sheets if necessary)

**APPLICANT**

William L. Trepicchio et

FILING DATE

**GROUP**

**May 9, 2001**

1623

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

[illegible]

Examiner

Date Considered

**\*EXAMINER:**

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

JAN 17 2002  
TECH CENTER 1000/29000

RECEIVED